← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
AKKARAJU SRINIVAS
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001253170
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 11
- Purchases · 24M
- 16
- Average purchase
- $5.0M
- Median purchase
- $1.7M
- Gross purchase value
- $79.3M
Companies: ALUMIS INC. | Kalaris Therapeutics, Inc. | Mineralys Therapeutics, Inc. | Neurogene Inc. | Scholar Rock Holding Corp
16 SEC accession(s) · 3 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-09 | ALUMIS INC. | ALMS | Director | $8.3M | Open filing |
| 2026-05-22 | Kalaris Therapeutics, Inc. | KLRS | Director | 10% Owner | $1.2M | Open filing |
| 2026-02-17 | Kalaris Therapeutics, Inc. | KLRS | Director | 10% Owner | $5.0M | Open filing |
| 2026-01-13 | ALUMIS INC. | ALMS | Director | $10.0M | Open filing |
| 2025-12-16 | Scholar Rock Holding Corp | SRRK | Director | $1.2M | Open filing |
| 2025-12-09 | ALUMIS INC. | ALMS | Director | $1.8M | Open filing |
| 2025-12-04 | ALUMIS INC. | ALMS | Director | $2.0M | Open filing |
| 2025-12-01 | ALUMIS INC. | ALMS | Director | $1.3M | Open filing |
| 2025-11-24 | ALUMIS INC. | ALMS | Director | $905.3K | Open filing |
| 2025-11-19 | ALUMIS INC. | ALMS | Director | $1.5M | Open filing |
| 2025-11-17 | ALUMIS INC. | ALMS | Director | $1.4M | Open filing |
| 2025-10-07 | Scholar Rock Holding Corp | SRRK | Director | $18.8M | Open filing |
| 2025-09-08 | Mineralys Therapeutics, Inc. | MLYS | Director | $15.0M | Open filing |
| 2025-05-06 | ALUMIS INC. | ALMS | Director | $1.5M | Open filing |
| 2025-03-17 | Mineralys Therapeutics, Inc. | MLYS | Director | $8.1M | Open filing |
| 2024-11-27 | Neurogene Inc. | NGNE | 10% Owner | $1.3M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 9Developing | 56.2% (9/16) | 66.7% (6/9) | +13.7% | +15.1% | -17.9% |
| 20D | 8Developing | 50.0% (8/16) | 75.0% (6/8) | +43.4% | +37.6% | -28.3% |
| 60D | 8Developing | 53.3% (8/15) | 87.5% (7/8) | +261.9% | +204.9% | -16.6% |
| 120D | 8Developing | 57.1% (8/14) | 87.5% (7/8) | +166.8% | +147.0% | -12.8% |
Research patterns
- First purchase in 12M
- 1/12
- Large purchase ≥ $100k
- 16/16
- Cluster buying · 15D
- 12/16
- Buying the dip
- 7/9
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.